Jump to Section...
Aliases
Databases
Disorders
Domains/Families
Drugs/Compounds
Expression
Function
Genomic Views
Intellectual Property
Medical News
Orthologs
Paralogs
Pathways/Interactions
Products
Proteins
Publications
Search Box
Summaries
Transcripts
Variants
TOP
BOTTOM
Aliases & Descriptionsfor HLA-DRB1 gene
(According to
1 HGNC ,
2 Entrez Gene ,
3 UniProtKB/Swiss-Prot ,
4 UniProtKB/TrEMBL , 5 OMIM , 6 GeneLoc
, and/or 7 Ensembl ,
8 miRBase )About This Section Aliases & Descriptions major histocompatibility complex, class II, DR beta 11 2 DR-143 DRw112 3 MHC class II antigen DRB1*163 DR12 3 MHC class II antigen DRB1*83 DR52 3 MHC class II antigen DRB1*113 DRw82 3 DR133 DRw102 3 DW2.2/DR2.23 DR82 3 DR43 DR-162 3 DR73 DR162 3 MHC class II antigen DRB1*73 DR-82 3 DR-133 HLA-DR1B2 5 MHC class II antigen DRB1*103 SS12 5 MHC class II antigen DRB1*33 MHC class II HLA-DR beta 1 chain2 DR-123 MHC class II HLA-DRw10-beta2 DR143 human leucocyte antigen DRB12 MHC class II antigen DRB1*43 HLA class II histocompatibility antigen, DR-1 beta chain2 DR-53 leucocyte antigen DRB12 DR123 DRB12 MHC class II antigen DRB1*153 FLJ750172 HLA-DRB23 HLA class II antigen beta chain2 DR-43 lymphocyte antigen DRB12 DR-73 MHC class II antigen HLA-DR132 DR93 HLA-DRB1*2 DR-93 FLJ763592 MHC class II antigen DRB1*133 HLA-DRB2 MHC class II antigen DRB1*123 leucocyte antigen DR beta 1 chain2 DR-13 HLA-DR-beta 12 MHC class II antigen DRB1*143 MHC class II HLA-DR-beta cell surface glycoprotein2 Clone P2-beta-33 MHC class II antigen DRB1*13 MHC class II antigen DRB1*93
Export aliases for HLA-DRB1 gene to outside databases Previous GC identifers: GC06U990049 GC06Md32547 GC06M032317 GC06Md32654 GC06M032656
Jump to Section...
Aliases
Databases
Disorders
Domains/Families
Drugs/Compounds
Expression
Function
Genomic Views
Intellectual Property
Medical News
Orthologs
Paralogs
Pathways/Interactions
Products
Proteins
Publications
Search Box
Summaries
Transcripts
Variants
TOP
BOTTOM
Summariesfor HLA-DRB1 gene (According to Entrez Gene ,
Tocris Bioscience ,
Wikipedia's
Gene Wiki ,
UniProtKB/Swiss-Prot ,
and/or
UniProtKB/TrEMBL )
About This Section Entrez Gene summary for HLA-DRB1 : HLA-DRB1 belongs to the HLA class II beta chain paralogs. The class II molecule is a heterodimer consisting of an alpha (DRA) and a beta chain (DRB), both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). The beta chain is approximately 26-28 kDa. It is encoded by 6 exons. Exon one encodes the leader peptide; exons 2 and 3 encode the two extracellular domains; exon 4 encodes the transmembrane domain; and exon 5 encodes the cytoplasmic tail. Within the DR molecule the beta chain contains all the polymorphisms specifying the peptide binding specificities. Hundreds of DRB1 alleles have been described and typing for these polymorphisms is routinely done for bone marrow and kidney transplantation. DRB1 is expressed at a level five times higher than its paralogs DRB3, DRB4 and DRB5. DRB1 is present in all individuals. Allelic variants of DRB1 are linked with either none or one of the genes DRB3, DRB4 and DRB5. There are 4 related pseudogenes: DRB2, DRB6, DRB7, DRB8 and DRB9. (provided by RefSeq) UniProtKB/Swiss-Prot: 2B1G_HUMAN, Q29974 Function : Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) andpresents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading Gene Wiki entry for HLA-DRB1
Jump to Section...
Aliases
Databases
Disorders
Domains/Families
Drugs/Compounds
Expression
Function
Genomic Views
Intellectual Property
Medical News
Orthologs
Paralogs
Pathways/Interactions
Products
Proteins
Publications
Search Box
Summaries
Transcripts
Variants
TOP
BOTTOM
Genomic Viewsfor HLA-DRB1 gene
(According to
GeneLoc and/or
HGNC , and/or
Entrez Gene (NCBI build 37) ,
and/or miRBase ,
Genomic Views according to
UCSC (hg19) and
Ensembl (release 60) ,
Regulatory elements and Epigenetics data according to
Qiagen and/or
SABiosciences )About This Section Regulatory elements: SABiosciences Regulatory transcription factor binding sites in the HLA-DRB1 gene promoter: NF-kappaB1 NF-kappaB CUTL1 c-Rel POU3F1 RelA C/EBPbeta LCR-F1 CP1C NF-Y Other transcription factors Search SABiosciences Chromatin IP Primers for HLA-DRB1 Epigenetics: QIAGEN PyroMark CpG Assay predesigned Pyrosequencing DNA Methylation assays
Genomic Location: Genomic View : UCSC Golden Path with GeneCards custom track Entrez Gene cytogenetic band: 6p21.3 Ensembl cytogenetic band: 6p21.32 HGNC cytogenetic band: 6p21.3 HLA-DRB1 Gene in genomic location: bands according to Ensembl, locations according to
(and/or Entrez Gene and/or Ensembl if different) GeneLoc gene densities for chromosome 6 GeneLoc Exon Structure
GeneLoc location for GC06M032546: view genomic region
(about GC identifiers )
Start:
32,546,546 bp from pter
End:
32,578,053 bp from pter
Size:
31,508 bases
Orientation:
minus strand
2 alternative locations : Chr 6-,ALT_REF_LOCI_2 32,515,135-32,528,486 Chr 6-,ALT_REF_LOCI_7 32,567,891-32,582,577
RefSeq DNA sequence: NC_000006.11 NT_007592.15 NT_113891.2 NT_167249.1
Jump to Section...
Aliases
Databases
Disorders
Domains/Families
Drugs/Compounds
Expression
Function
Genomic Views
Intellectual Property
Medical News
Orthologs
Paralogs
Pathways/Interactions
Products
Proteins
Publications
Search Box
Summaries
Transcripts
Variants
TOP
BOTTOM
Proteinsfor HLA-DRB1 gene
(According to
1 UniProtKB ,
neXtProt ,
and/or Ensembl ,
Phosphorylation sites according to 2 Phosphosite ,
RefSeq according to NCBI ,
PDB rendering according to OCA and/or Proteopedia ,
Recombinant Proteins
from
Millipore ,
Sigma-Aldrich ,
R&D Systems ,
GenScript ,
Enzo Life Sciences ,
OriGene ,
Novus Biologicals ,
Sino Biological , and/or
ProSpec ,
Biochemical Assays by
Millipore ,
Sigma-Aldrich ,
R&D Systems ,
OriGene ,
GenScript ,
Cell Signaling Technology ,
Enzo Life Sciences , and/or
Uscn ,
Ontologies according to Gene
Ontology Consortium 01 Dec 2010 and
Entrez Gene ,
Antibodies by
Millipore ,
Sigma-Aldrich ,
R&D Systems ,
GenScript ,
Cell Signaling Technology ,
OriGene ,
Novus Biologicals , and/or
Epitomics )
About This Section UniProtKB/Swiss-Prot: 2B11_HUMAN, P04229 (See
protein sequence )Recommended Name: HLA class II histocompatibility antigen, DRB1-1 beta chain precursor Size : 266 amino acids; 29914 Da
Subunit : Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmicreticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of antigenic peptides
Subcellular location : Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-passtype I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
PDB structures from and Proteopedia : 1AQD (3D)
 1DLH (3D)
 1FYT (3D)
 1HXY (3D)
 1JWM (3D)
 1JWS (3D)
 1JWU (3D)
 1KG0 (3D)
 1KLG (3D)
 1KLU (3D)
 1LO5 (3D)
 1PYW (3D)
 1R5I (3D)
 1SEB (3D)
 1SJE (3D)
 1SJH (3D)
 1T5W (3D)
 1T5X (3D)
 2FSE (3D)
 2G9H (3D)
 2IAM (3D)
 2IAN (3D)
 2ICW (3D)
 2IPK (3D)
 2OJE (3D)
 3L6F (3D)
 
Secondary accessions : A4F5N0 A8K098 O62869 P13758 Q06662 Q30116 Q30117 Q5Y7E9 Q7M2H4 Q95461 Q9BCL7Q9GIK5 Q9MXZ0 Q9MXZ5 Q9TQ91 UniProtKB/Swiss-Prot: 2B13_HUMAN, P01912 (See
protein sequence )
Recommended Name: HLA class II histocompatibility antigen, DRB1-3 chain precursor Size : 266 amino acids; 30120 Da
Subunit : Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmicreticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of antigenic peptides
Subcellular location : Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-passtype I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
PDB structures from and Proteopedia : 1A6A (3D)
 UniProtKB/Swiss-Prot: 2B14_HUMAN, P13760 (See
protein sequence )
Recommended Name: HLA class II histocompatibility antigen, DRB1-4 beta chain precursor Size : 266 amino acids; 30112 Da
Subunit : Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmicreticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of antigenic peptides
Subcellular location : Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-passtype I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
PDB structures from and Proteopedia : 1D5M (3D)
 1D5X (3D)
 1D5Z (3D)
 1D6E (3D)
 1J8H (3D)
 2SEB (3D)
 
Secondary accessions : O19717 O19739 P13759 Q29875 Q30145 Q9GIX9 Q9GIY4 Q9MY13 Q9XRY5UniProtKB/Swiss-Prot: 2B17_HUMAN, P13761 (See
protein sequence )
Recommended Name: HLA class II histocompatibility antigen, DRB1-7 beta chain precursor Size : 266 amino acids; 29822 Da
Subunit : Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmicreticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of antigenic peptides
Subcellular location : Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-passtype I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
Secondary accessions : B0UYW1 O46699 O46872UniProtKB/Swiss-Prot: 2B18_HUMAN, Q30134 (See
protein sequence )
Recommended Name: HLA class II histocompatibility antigen, DRB1-8 beta chain precursor Size : 266 amino acids; 30004 Da
Subunit : Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmicreticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of antigenic peptides
Subcellular location : Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-passtype I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
Secondary accessions : O19718 O19788 Q29968 Q30108 Q30115 Q9BCP0 Q9BCP1 Q9BCP2 Q9BD33 Q9TQ37 Q9UIM9UniProtKB/Swiss-Prot: 2B19_HUMAN, Q9TQE0 (See
protein sequence )
Recommended Name: HLA class II histocompatibility antigen, DRB1-9 beta chain precursor Size : 266 amino acids; 29826 Da
Subunit : Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmicreticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of antigenic peptides
Subcellular location : Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-passtype I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
Secondary accessions : Q30149UniProtKB/Swiss-Prot: 2B1A_HUMAN, Q30167 (See
protein sequence )
Recommended Name: HLA class II histocompatibility antigen, DRB1-10 beta chain precursor Size : 266 amino acids; 30002 Da
Subunit : Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmicreticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of antigenic peptides
Subcellular location : Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-passtype I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
Secondary accessions : P01914 Q9MYF5UniProtKB/Swiss-Prot: 2B1B_HUMAN, P20039 (See
protein sequence )
Recommended Name: HLA class II histocompatibility antigen, DRB1-11 beta chain precursor Size : 266 amino acids; 30160 Da
Subunit : Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmicreticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of antigenic peptides
Subcellular location : Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-passtype I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
Secondary accessions : Q30006 Q9GIX8UniProtKB/Swiss-Prot: 2B1C_HUMAN, Q95IE3 (See
protein sequence )
Recommended Name: HLA class II histocompatibility antigen, DRB1-12 beta chain precursor Size : 266 amino acids; 29878 Da
Subunit : Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmicreticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of antigenic peptides
Subcellular location : Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-passtype I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
Secondary accessions : A7LA26 B0LUZ6 B6VCX2 B7UDB2 O19585 Q19AF2 Q29771 Q2L9H4 Q2MZ92 Q5EER6 Q5NDB9Q5UT58 Q5Y7G0 Q768U4 Q7YP04 Q861H8 Q95IT6 Q9BD40 UniProtKB/Swiss-Prot: 2B1D_HUMAN, Q5Y7A7 (See
protein sequence )
Recommended Name: HLA class II histocompatibility antigen, DRB1-13 beta chain precursor Size : 266 amino acids; 30008 Da
Subunit : Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmicreticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of antigenic peptides
Subcellular location : Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-passtype I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
Sequence caution : Sequence=CAB40418.1; Type=Erroneous gene model prediction;
Secondary accessions : A0MWF2 A2ICT1 A4ZXA5 A4ZXA6 A7UHG2 A7X5K7 A8YQE9 B0BK85 B3VTQ3 B5A8Y2 B5A8Y3B5B9V6 B5QSK8 C0LAB5 O02930 O62889 O78047 P79545 Q14280 Q14QT2 Q19K86 Q1G0Z9 Q1KLJ6 Q29673 Q29720 Q29722 Q29806 Q29833 Q29874 Q29886 Q2MF40 Q2YHQ2 Q30112 Q3LA93 Q3LA94 Q3LA95 Q3LA96 Q3LA97 Q3LA98 Q3LA99 Q3LAA0 Q3LAA1 Q3LAA2 Q3MQ60 Q53IG1 Q56FP2 Q56FP3 Q58F52 Q5K3W2 Q5UBA2 Q5W3L4 Q6REE2 Q6U387 Q701T1 Q70Q85 Q768U2 Q7YP03 Q7YQ26 Q7YQA3 Q860E5 Q860H8 Q860Z3 Q861G6 Q861H0 Q861H4 Q8HWQ6 Q8WMA0 Q95389 Q95HL1 Q96HZ9 Q9BCP5 Q9BD21 Q9GIP3 Q9GJ25 Q9GJ60 Q9GJF8 Q9GJF9 Q9GJG0 Q9MY45 Q9MY56 Q9TPW3 Q9TPW9 Q9TPX4 Q9UBY1 Q9UIN0 Q9XRX1 Q9Y453 UniProtKB/Swiss-Prot: 2B1E_HUMAN, Q9GIY3 (See
protein sequence )
Recommended Name: HLA class II histocompatibility antigen, DRB1-14 beta chain precursor Size : 266 amino acids; 30139 Da
Subunit : Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmicreticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of antigenic peptides
Subcellular location : Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-passtype I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
Sequence caution : Sequence=CAB45249.1; Type=Erroneous gene model prediction;
Secondary accessions : A0N0W1 A2TGX3 A4ZY86 A5H000 A5HKN8 A7DZP9 A7X5B1 A7X5B7 A7X5E0 A7X5E6 A7X5H8A9JPG0 B1GWE7 B2CR03 B2LVF9 B2NJ29 B2ZCY1 B3VTP8 B5B8U0 B5B9V5 B5LZ25 B6VEL9 B9VRA4 B9X248 O02876 O46793 O77969 O78210 Q0PQ39 Q155F7 Q1AP33 Q1JRP3 Q27PR6 Q27PR7 Q29734 Q29770 Q29772 Q29800 Q2A120 Q2HZE5 Q2LE76 Q2MJA6 Q2VQU1 Q307W5 Q31636 Q3LA87 Q3LA88 Q3LA89 Q3LA90 Q3LA91 Q3LA92 Q3T919 Q4PRC3 Q4PRC5 Q4VZY7 Q56FP1 Q5BM92 Q5U9W6 Q683P7 Q70GL2 Q7YNY9 Q7YQA5 Q860D8 Q860D9 Q860S0 Q861H5 Q861H7 Q8MH59 Q8MH60 Q8WLU3 Q95348 Q95HK1 Q95HL0 Q95IG2 Q9GIL5 Q9GIL6 Q9GIY0 Q9GIY1 Q9GIY2 Q9GJ56 Q9GJ57 Q9GJ58 Q9TPB6 Q9TPW1 Q9XRY4 Q9Y4H7 UniProtKB/Swiss-Prot: 2B1F_HUMAN, P01911 (See
protein sequence )
Recommended Name: HLA class II histocompatibility antigen, DRB1-15 beta chain precursor Size : 266 amino acids; 29966 Da
Subunit : Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmicreticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of antigenic peptides
Subcellular location : Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-passtype I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
Miscellaneous : The chain shown constituted about 70% of a pool of at least seven similar beta chains
PDB structures from and Proteopedia : 1BX2 (3D)
 1YMM (3D)
 2WBJ (3D)
 
Secondary accessions : Q29790 Q29975 Q30142 Q30166 Q32MY7 Q56FN9 Q5Y7B0 Q5Y7B9UniProtKB/Swiss-Prot: 2B1G_HUMAN, Q29974 (See
protein sequence )
Recommended Name: HLA class II histocompatibility antigen, DRB1-16 beta chain precursor Size : 266 amino acids; 30030 Da
Subunit : Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmicreticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of antigenic peptides
Subcellular location : Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-passtype I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
Secondary accessions : A7X5J4 O98212 Q0PGR5 Q29792 Q30120 Q30159 Q30200 Q3HUP9 Q3KTM1 Q3LA84 Q6T865Q95383 Explore the universe of human proteins at neXtProt for HLA-DRB1: NX_Q29974 Post-translational modifications:
Ubiquitinated by MARCH1 and MARCH8 at Lys-254 leading to sorting into the endosome system and down-regulation of MHC class II (Probable)1
View phosphorylation sites using PhosphoSite 2
REFSEQ proteins: NP_002115.2 ENSEMBL proteins: ENSP00000353099 Human Recombinant Proteins 5/11 Gene Ontology (GO) cellular component terms (GO ID links to tree view) (see all 11 ):
About this table
HLA-DRB1 for ontologies About GeneDecksing Antibodies for HLA-DRB1: Assays for HLA-DRB1:
Jump to Section...
Aliases
Databases
Disorders
Domains/Families
Drugs/Compounds
Expression
Function
Genomic Views
Intellectual Property
Medical News
Orthologs
Paralogs
Pathways/Interactions
Products
Proteins
Publications
Search Box
Summaries
Transcripts
Variants
TOP
BOTTOM
Protein
Domains/ Familiesfor HLA-DRB1 gene (According to InterPro , ProtoNet ,
UniProtKB , and/or BLOCKS ,
Sets of similar genes according to GeneDecks )
About This Section
HLA-DRB1 for domains About GeneDecksing 5/7 InterPro domains/families (see all 7 ):
Graphical View of Domain Structure for InterPro Entry P04229 Graphical View of Domain Structure for InterPro Entry P01912 Graphical View of Domain Structure for InterPro Entry P13760 Graphical View of Domain Structure for InterPro Entry P13761 Graphical View of Domain Structure for InterPro Entry Q30134 Graphical View of Domain Structure for InterPro Entry Q9TQE0 Graphical View of Domain Structure for InterPro Entry Q30167 Graphical View of Domain Structure for InterPro Entry P20039 Graphical View of Domain Structure for InterPro Entry Q95IE3 Graphical View of Domain Structure for InterPro Entry Q5Y7A7 Graphical View of Domain Structure for InterPro Entry Q9GIY3 Graphical View of Domain Structure for InterPro Entry P01911 Graphical View of Domain Structure for InterPro Entry Q29974 ProtoNet protein and cluster: P04229
2 Blocks protein families : IPB000353 Class II histocompatibility antigen IPB003597 Immunoglobulin C-type UniProtKB/Swiss-Prot: 2B11_HUMAN, P04229 Similarity : Belongs to the MHC class II familySimilarity : Contains 1 Ig-like C1-type (immunoglobulin-like) domain
UniProtKB/Swiss-Prot: 2B13_HUMAN, P01912 Similarity : Belongs to the MHC class II familySimilarity : Contains 1 Ig-like C1-type (immunoglobulin-like) domain
UniProtKB/Swiss-Prot: 2B14_HUMAN, P13760 Similarity : Belongs to the MHC class II familySimilarity : Contains 1 Ig-like C1-type (immunoglobulin-like) domain
UniProtKB/Swiss-Prot: 2B17_HUMAN, P13761 Similarity : Belongs to the MHC class II familySimilarity : Contains 1 Ig-like C1-type (immunoglobulin-like) domain
UniProtKB/Swiss-Prot: 2B18_HUMAN, Q30134 Similarity : Belongs to the MHC class II familySimilarity : Contains 1 Ig-like C1-type (immunoglobulin-like) domain
UniProtKB/Swiss-Prot: 2B19_HUMAN, Q9TQE0 Similarity : Belongs to the MHC class II familySimilarity : Contains 1 Ig-like C1-type (immunoglobulin-like) domain
UniProtKB/Swiss-Prot: 2B1A_HUMAN, Q30167 Similarity : Belongs to the MHC class II familySimilarity : Contains 1 Ig-like C1-type (immunoglobulin-like) domain
UniProtKB/Swiss-Prot: 2B1B_HUMAN, P20039 Similarity : Belongs to the MHC class II familySimilarity : Contains 1 Ig-like C1-type (immunoglobulin-like) domain
UniProtKB/Swiss-Prot: 2B1C_HUMAN, Q95IE3 Similarity : Belongs to the MHC class II familySimilarity : Contains 1 Ig-like C1-type (immunoglobulin-like) domain
UniProtKB/Swiss-Prot: 2B1D_HUMAN, Q5Y7A7 Similarity : Belongs to the MHC class II familySimilarity : Contains 1 Ig-like C1-type (immunoglobulin-like) domain
UniProtKB/Swiss-Prot: 2B1E_HUMAN, Q9GIY3 Similarity : Belongs to the MHC class II familySimilarity : Contains 1 Ig-like C1-type (immunoglobulin-like) domain
UniProtKB/Swiss-Prot: 2B1F_HUMAN, P01911 Similarity : Belongs to the MHC class II familySimilarity : Contains 1 Ig-like C1-type (immunoglobulin-like) domain
UniProtKB/Swiss-Prot: 2B1G_HUMAN, Q29974 Similarity : Belongs to the MHC class II familySimilarity : Contains 1 Ig-like C1-type (immunoglobulin-like) domain
Jump to Section...
Aliases
Databases
Disorders
Domains/Families
Drugs/Compounds
Expression
Function
Genomic Views
Intellectual Property
Medical News
Orthologs
Paralogs
Pathways/Interactions
Products
Proteins
Publications
Search Box
Summaries
Transcripts
Variants
TOP
BOTTOM
Gene Functionfor HLA-DRB1 gene
(According to UniProtKB ,
IUBMB ,and/or
Genatlas , Animal models from MGI Dec 24 2010,
shRNA from
OriGene ,
Sigma-Aldrich ,
RNAi from
Millipore ,
siRNAs from
Sigma-Aldrich ,
OriGene ,
Qiagen ,
Super-pooled esiRNAs from Sigma-Aldrich ,
microRNA from Sigma-Aldrich ,
Qiagen ,
SABiosciences ,
Clones from Millipore ,
Sigma-Aldrich ,
OriGene ,
GenScript ,
Sino Biological ,
Cell Lines from GenScript ,
Ontologies according to Gene Ontology Consortium 01 Dec 2010 via
Entrez Gene .)
About This Section UniProtKB/Swiss-Prot: 2B11_HUMAN, P04229 Function : Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) andpresents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route; where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules; and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments; exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides; autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs; other cells of the gastrointestinal tract; such as epithelial cells; express MHC class II molecules and CD74 and act as APCs; which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen; three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs; CD74 undergoes a sequential degradation by various proteases; including CTSS and CTSL; leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B cells; the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules; increased acidification produces increased proteolysis and efficient peptide loading
UniProtKB/Swiss-Prot: 2B13_HUMAN, P01912 Function : Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) andpresents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route; where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules; and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments; exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides; autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs; other cells of the gastrointestinal tract; such as epithelial cells; express MHC class II molecules and CD74 and act as APCs; which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen; three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs; CD74 undergoes a sequential degradation by various proteases; including CTSS and CTSL; leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B cells; the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules; increased acidification produces increased proteolysis and efficient peptide loading
UniProtKB/Swiss-Prot: 2B14_HUMAN, P13760 Function : Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) andpresents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route; where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules; and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments; exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides; autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs; other cells of the gastrointestinal tract; such as epithelial cells; express MHC class II molecules and CD74 and act as APCs; which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen; three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs; CD74 undergoes a sequential degradation by various proteases; including CTSS and CTSL; leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B cells; the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules; increased acidification produces increased proteolysis and efficient peptide loading
UniProtKB/Swiss-Prot: 2B17_HUMAN, P13761 Function : Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) andpresents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route; where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules; and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments; exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides; autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs; other cells of the gastrointestinal tract; such as epithelial cells; express MHC class II molecules and CD74 and act as APCs; which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen; three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs; CD74 undergoes a sequential degradation by various proteases; including CTSS and CTSL; leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B cells; the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules; increased acidification produces increased proteolysis and efficient peptide loading
UniProtKB/Swiss-Prot: 2B18_HUMAN, Q30134 Function : Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) andpresents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route; where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules; and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments; exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides; autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs; other cells of the gastrointestinal tract; such as epithelial cells; express MHC class II molecules and CD74 and act as APCs; which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen; three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs; CD74 undergoes a sequential degradation by various proteases; including CTSS and CTSL; leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B cells; the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules; increased acidification produces increased proteolysis and efficient peptide loading
UniProtKB/Swiss-Prot: 2B19_HUMAN, Q9TQE0 Function : Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) andpresents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route; where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules; and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments; exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides; autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs; other cells of the gastrointestinal tract; such as epithelial cells; express MHC class II molecules and CD74 and act as APCs; which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen; three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs; CD74 undergoes a sequential degradation by various proteases; including CTSS and CTSL; leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B cells; the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules; increased acidification produces increased proteolysis and efficient peptide loading
UniProtKB/Swiss-Prot: 2B1A_HUMAN, Q30167 Function : Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) andpresents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route; where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules; and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments; exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides; autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs; other cells of the gastrointestinal tract; such as epithelial cells; express MHC class II molecules and CD74 and act as APCs; which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen; three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs; CD74 undergoes a sequential degradation by various proteases; including CTSS and CTSL; leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B cells; the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules; increased acidification produces increased proteolysis and efficient peptide loading
UniProtKB/Swiss-Prot: 2B1B_HUMAN, P20039 Function : Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) andpresents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading
UniProtKB/Swiss-Prot: 2B1C_HUMAN, Q95IE3 Function : Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) andpresents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading
UniProtKB/Swiss-Prot: 2B1D_HUMAN, Q5Y7A7 Function : Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) andpresents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading
UniProtKB/Swiss-Prot: 2B1E_HUMAN, Q9GIY3 Function : Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) andpresents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading
UniProtKB/Swiss-Prot: 2B1F_HUMAN, P01911 Function : Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) andpresents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading
UniProtKB/Swiss-Prot: 2B1G_HUMAN, Q29974 Function : Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) andpresents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading
Genatlas biochemistry entry for HLA-DRB1 :HLA-DR,beta 1 chain,determining DR1,3,4,5 etc 2 Gene Ontology (GO) molecular function terms (GO ID links to tree view) :
About this table
HLA-DRB1 for ontologies About GeneDecksing
Jump to Section...
Aliases
Databases
Disorders
Domains/Families
Drugs/Compounds
Expression
Function
Genomic Views
Intellectual Property
Medical News
Orthologs
Paralogs
Pathways/Interactions
Products
Proteins
Publications
Search Box
Summaries
Transcripts
Variants
TOP
BOTTOM
Pathways & Interactionsfor HLA-DRB1 gene
(Pathways according to
Millipore ,
Cell Signaling Technology ,
Sigma-Aldrich ,
KEGG
and/or UniProtKB ,
Sets of similar genes according to GeneDecks ,
PCR Arrays from
SABiosciences ,
Proteins Network according to
SABiosciences ,
Sigma-Aldrich ,
Interactions according to 1 UniProtKB ,
2 MINT , and/or
3 STRING ,
with links to IntAct and
Ensembl ,
Ontologies according to Gene Ontology Consortium 01 Dec 2010 via
Entrez Gene) .
About This Section
HLA-DRB1 for pathways About GeneDecksing 5/6 Millipore Pathways for HLA-DRB1 (see all 6 )5/22 Sigma-Aldrich "Your Favorite Gene" (powered by Ingenuity) Pathways for HLA-DRB1 (see all 22 )5/15 Kegg Pathways (Kegg details for HLA-DRB1) (see all 15 ): SABiosciences Pathway-Focused PCR Array including HLA-DRB1 : PAHS-3401A Sigma-Aldrich "Your Favorite Gene" (powered by Ingenuity) Molecular Interaction Network for HLA-DRB1 SABiosciences Gene Network CentralTM Interacting Genes and Proteins Network for HLA-DRB1 5/61 Interacting proteins for HLA-DRB1 (P01912 2 P04229 2 , 2 ENSP00000353099 3 ) via UniProtKB, MINT, and/or STRING (see all 61 )About this table 5 Gene Ontology (GO) biological process terms (GO ID links to tree view) :
GO ID Qualified GO term Evidence PubMed IDs GO:0002504 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II
IEA -- GO:0006955 immune response
NAS 3129499 GO:0019882 antigen processing and presentation
-- -- GO:0031295 T cell costimulation
TAS -- GO:0050852 T cell receptor signaling pathway
TAS --
About this table
HLA-DRB1 for ontologies About GeneDecksing
Jump to Section...
Aliases
Databases
Disorders
Domains/Families
Drugs/Compounds
Expression
Function
Genomic Views
Intellectual Property
Medical News
Orthologs
Paralogs
Pathways/Interactions
Products
Proteins
Publications
Search Box
Summaries
Transcripts
Variants
TOP
BOTTOM
Drugs & Compoundsfor HLA-DRB1 gene (Chemical Compounds according to UniProtKB , Enzo Life Sciences ,
Sigma-Aldrich , Tocris Bioscience , and/or
Novoseek and Drugs according to
Enzo Life Sciences and/or
PharmGKB )
About This Section
HLA-DRB1 for compounds About GeneDecksing Browse Tocris compounds for HLA-DRB1 10/17 Novoseek chemical compound relationships for HLA-DRB1 gene (see all 17 )
Compound
-log (P-Val)
Hits
PubMed IDs for Articles with Shared Sentences (# sentences)
dr-10
77.3
6
7780115 (1), 9550403 (1), 8754259 (1), 10626740 (1)
dr-16
73.6
1
9243764 (1)
dpa 1
73.1
5
8782076 (1), 8863870 (1), 17060025 (1), 10616003 (1) (see all 5 )
oligonucleotide
53.4
22
8117375 (1), 12823773 (1), 15865503 (1), 18718089 (1) (see all 20 )
gold sodium thiomalate
36
2
11093435 (1)
valine
30.5
4
9098452 (1), 8500529 (1), 10439317 (1), 2369430 (1)
amino acid
19.7
1
1533151 (1)
c-peptide
4.17
1
15388265 (1)
atp
3.36
2
12658812 (2)
lysine
0
2
7738179 (1), 7612412 (1)
About this table 1 PharmGKB drug compound relationship for HLA-DRB1 gene
Drug compound
PharmGKB Relations
PubMed IDs for articles supporting these relationships
cyclosporine PD  9277043
About this table
Jump to Section...
Aliases
Databases
Disorders
Domains/Families
Drugs/Compounds
Expression
Function
Genomic Views
Intellectual Property
Medical News
Orthologs
Paralogs
Pathways/Interactions
Products
Proteins
Publications
Search Box
Summaries
Transcripts
Variants
TOP
BOTTOM
Transcriptsfor HLA-DRB1 gene (GenBank/EMBL/DDBJ Accessions according to
Unigene
(Build 228 Homo sapiens; Dec 8 2010) or GenBank , RefSeq according to Entrez Gene ,
DOTS (version 10), and/or
AceView ,
transcript ids from Ensembl
with links to UCSC ,
non coding RNAs according to
RNAdb ,
ESTs according to GeneTide ,
exon structure from GeneLoc ,
alternative splicing isoforms according to ASD and/or
ECgene ,
RNAi Products from
Millipore ,
siRNAs from
Sigma-Aldrich ,
OriGene ,
Qiagen ,
Super-pooled esiRNAs from Sigma-Aldrich ,
shRNA from
Sigma-Aldrich ,
OriGene ,
microRNA from Sigma-Aldrich ,
Qiagen ,
SABiosciences ,
Tagged/untagged cDNA clones from
OriGene ,
Sigma-Aldrich ,
GenScript ,
Primers from
OriGene and/or
SABiosciences )About This Section REFSEQ mRNAs for HLA-DRB1 gene: NM_002124.2
Additional cDNA sequence: AF000448.1 AF010142.1 AF017439.1 AF017440.1 AF017441.1 AF048707.1 AF192258.1 AF192259.1 AF199236.2 AF291675.1 AF361548.1 AF361549.1 AF436097.1 AF522251.1 AJ245881.1 AJ297583.1 AJ297584.1 AJ297585.1 AJ297586.2 AJ297587.1 AJ302075.1 AJ536121.1 AJ697892.1 AJ697893.1 AK225683.1 AK225690.1 AK226043.1 AK226058.1 AK289463.1 AK291499.1 AK291987.1 AK292151.1 AK293020.1 AM056024.1 AY052550.1 AY054375.1 AY138123.1 AY626551.1 AY626552.1 AY770514.1 AY935719.1 AY961062.1 AY961063.1 AY961064.1 AY961065.1 AY961066.1 AY961067.1 AY961068.1 AY961069.1 AY961070.2 AY961071.2 AY961072.1 AY961073.1 AY961074.1 AY961075.1 AY961076.1 AY961077.1 AY961078.1 BC001023.2 BC005312.1 BC007920.2 BC008403.1 BC008987.1 BC018832.2 BC018834.2 BC018835.2 BC024269.1 BC031023.1 BC033827.1 BC106057.1 BC108922.1 BC171883.1 CR592036.1 CR600239.1 CR601907.1 CR603301.1 CR603446.1 CR609601.1 CR609994.1 CR610561.1 CR613356.1 CR625333.1 DQ002917.1 DQ090958.1 DQ140279.1 DQ284431.1 DQ284432.1 DQ284433.1 DQ284435.1 EU375850.1 FJ200455.1 GQ891550.1 GQ891551.1 HM067843.1 HM067844.1 HM067845.1 HM067846.1 HM067847.1 HM067848.1 HM067849.1 HM067850.1 HM067851.1 HM067852.1 HM067853.1 HM067854.1 HM067855.1 HM067856.1 HM067857.1 HM067858.1 HM067859.1 HM067860.1 HM067861.1 HM067862.1 HM067863.1 L02545.1 L42143.1 L76133.1 M11161.1 M11867.1 M14191.1 M14661.1 M14662.1 M15068.1 M15179.1 M16731.1 M16941.1 M16942.1 M16957.1 M16958.1 M16959.1 M17378.1 M17380.1 M17381.1 M17385.1 M20138.1 M20430.1 M20504.1 M21008.1 M25265.1 M26038.1 M27126.1 M27635.1 M28583.1 M28584.1 M28991.1 M28992.1 M30179.1 M30180.1 M33600.1 M35980.1 M35981.1 M35982.1 M59803.1 S79787.1 U09201.1 U17379.1 U35375.1 U35729.1 U37433.1 U37582.1 U56640.1 U65585.1 U66825.1 U70544.1 U83583.1 U83584.1 U84892.1 U95817.1 U95819.1 U95820.1 U95989.1 V00522.1 X00699.1 X00700.1 X02902.1 X03069.1 X12544.1 X99896.1
24/72 DOTS entries (see all 72 ): DT.92410344 DT.91706875 DT.92028787 DT.95164729 DT.100776434 DT.92047682 DT.95164752 DT.92382901
DT.95164731 DT.121314547 DT.87079048 DT.40115364 DT.100781798 DT.100778733 DT.100650571 DT.100766538 DT.92380890 DT.121314746 DT.121314807 DT.97857272 DT.95230813 DT.92467723 DT.95164743 DT.91802323 24/89 AceView cDNA sequences (see all 89 ):
M16731 BV201637 M17381 AJ536121 BC024269 AJ297586 AF291675 L42143 BV207240 AH002891 AJ245881 BV207185 M15073 BV183568 X02902 BV183567 M15069 BV207036 X12544 BV200472 U84892 BV200461 BV207215 BV207191
highest scoring ESTs for HLA-DRB1 :AJ011065 AU099634 AY626552 AY770514 BC108922 BF976113 BI761102 BM770494 BQ066389 CD102759 Unigene Clusters for HLA-DRB1:
Major histocompatibility complex, class II, DR beta 1 Hs.534322 [show with all ESTs ] , Hs.696211 [show with all ESTs ] Unigene Representative Sequences: AK290388 , AK225690 GeneLoc Exon Structure 2 Ensembl transcripts including schematic representations, and UCSC links where relevant : ENST00000360004 (uc011dqb.1 uc011dqa.1 uc011dqc.1 uc003obp.3 )ENST00000480500
Jump to Section...
Aliases
Databases
Disorders
Domains/Families
Drugs/Compounds
Expression
Function
Genomic Views
Intellectual Property
Medical News
Orthologs
Paralogs
Pathways/Interactions
Products
Proteins
Publications
Search Box
Summaries
Transcripts
Variants
TOP
BOTTOM
Expression for HLA-DRB1 gene
(Experimental results according to
1 GeneNote
and GNF BioGPS ,
probe sets-to-genes annotations according to
2 GeneAnnot ,
3 GeneTide ,
Sets of similar genes according to GeneDecks ,
Electronic Northern calculations according to data from
UniGene (Build 228 Homo sapiens),
SAGE tags according to
CGAP ,
plus additional links to
SOURCE , and/or
GNF
BioGPS , and/or
EXPOLDB , and/or
UniProtKB ,
Primers from
OriGene and/or
SABiosciences
)
About This Section HLA-DRB1 expression in normal and diseased human tissues 1 / 2 / 3
10 probe-sets matching HLA-DRB1 gene
Affymetrix probe-set
Array
GeneAnnot data
GeneNote data
GeneTide data
# genes
Sensitivity
Specificity
Correlation
Length
Gb_Accession
Consensus
Uniqueness
Score
Rank
41723_s_at2 , 3
U95-A
19
1.00
0.10
0.98
0.81
M32578
0.60
0.33
0.48
2
75284_f_at2 , 3
U95-D
9
0.88
0.45
0.98
1.19
T88824
0.40
0.44
0.42
1
209312_x_at2 , 3
U133-A
15
1.00
0.16
--
--
U65585
0.40
0.50
0.45
1
215193_x_at2 , 3
U133-A
23
1.00
0.13
--
--
AJ297586
0.40
0.67
0.55
1
204670_x_at2 , 3
U133-A
11
0.91
0.26
--
--
NM_002125
0.40
0.50
0.45
1
208306_x_at2 , 3
U133-A
11
0.64
0.14
--
--
NM_021983
0.20
0.50
0.38
1
209312_x_at2
U133Plus2
15
1.00
0.16
--
--
--
--
--
--
--
215193_x_at2
U133Plus2
23
1.00
0.13
--
--
--
--
--
--
--
204670_x_at2
U133Plus2
11
0.91
0.26
--
--
--
--
--
--
--
208306_x_at2
U133Plus2
11
0.64
0.14
--
--
--
--
--
--
--
About this table
HLA-DRB1 for expression About GeneDecksing Data from
Genenote  
(Publications) and GNF BioGPS About these images About these images CGAP SAGE TAG: CATCTGTACT GAGTTAAAAA SOURCE GeneReport for Unigene clusters: Hs.534322 Hs.696211 SABiosciences Expression via Pathway-Focused PCR Array including HLA-DRB1 : PAHS-3401A
Jump to Section...
Aliases
Databases
Disorders
Domains/Families
Drugs/Compounds
Expression
Function
Genomic Views
Intellectual Property
Medical News
Orthologs
Paralogs
Pathways/Interactions
Products
Proteins
Publications
Search Box
Summaries
Transcripts
Variants
TOP
BOTTOM
Orthologsfor HLA-DRB1 gene
(Orthologs according to
1,2 HomoloGene (2 older version, for species not in 1 newer version),
3 euGenes ,
4 SGD
and/or
5 MGI Dec 24 2010,
with possible further links to
Flybase
and/or
WormBase ,
Gene Trees according to Ensembl )
About This Section
Orthologs for HLA-DRB1 gene from 5/7 species (see all 7 )
About this table Species with no ortholog for HLA-DRB1 ENSEMBL Gene Tree for HLA-DRB1 (if available)
Jump to Section...
Aliases
Databases
Disorders
Domains/Families
Drugs/Compounds
Expression
Function
Genomic Views
Intellectual Property
Medical News
Orthologs
Paralogs
Pathways/Interactions
Products
Proteins
Publications
Search Box
Summaries
Transcripts
Variants
TOP
BOTTOM
Paralogsfor HLA-DRB1 gene (Paralogs according to 1 HomoloGene and 2 Ensembl , Pseudogenes according to 3 Pseudogene.org )About This Section Paralogs for HLA-DRB1 gene HLA-DQB2 2 HLA-DRB5 2 ENSG00000248993 2 HLA-DQB1 2 HLA-DPB2 2 HLA-DMB 2 HLA-DOB 2 HLA-DPB1 2
HLA-DRB1 for paralogs About GeneDecksing
Jump to Section...
Aliases
Databases
Disorders
Domains/Families
Drugs/Compounds
Expression
Function
Genomic Views
Intellectual Property
Medical News
Orthologs
Paralogs
Pathways/Interactions
Products
Proteins
Publications
Search Box
Summaries
Transcripts
Variants
TOP
BOTTOM
Genomic Variantsfor HLA-DRB1 gene (SNPs according to the
1 NCBI SNP Database ,
2 Ensembl ,
3 PupaSUITE , and
UniProtKB ,
Linkage Disequilibrium by HapMap ,
Structural Variations(CNVs/InDels/Inversions) from the Database of Genomic Variants , Resequencing Primers from Qiagen )
About This Section UniProtKB/Swiss-Prot: 2B1G_HUMAN, Q29974 Polymorphism : The following alleles of DRB1-1 are known: DRB1*01:01; DRB1*01:02; DRB1*01:03; DRB1*01:04; DRB1*01:05;DRB1*01:06; DRB1*01:07; DRB1*01:08; DRB1*01:09; DRB1*01:10; DRB1*01:11; DRB1*01:12; DRB1*01:13; DRB1*01:14; DRB1*01:15; DRB1*01:16; DRB1*01:17; DRB1*01:18; DRB1*01:19; DRB1*01:20 and DRB1*01:21. The sequence shown is that of DRB1*01:01 Polymorphism : The following alleles of DRB1-3 are known: DRB1*03:01; DRB1*03:02; DRB1*03:03; DRB1*03:04; DRB1*03:05;DRB1*03:06; DRB1*03:07; DRB1*03:08; DRB1*03:09; DRB1*03:10; DRB1*03:11; DRB1*03:12; DRB1*03:13; DRB1*03:14; DRB1*03:15; DRB1*03:16; DRB1*03:17; DRB1*03:18; DRB1*03:19; DRB1*03:20; DRB1*03:21; DRB1*03:22; DRB1*03:23; DRB1*03:24; DRB1*03:25; DRB1*03:26; DRB1*03:27; DRB1*03:28; DRB1*03:29; DRB1*03:30; DRB1*03:31; DRB1*03:32; DRB1*03:33; DRB1*03:34; DRB1*03:35; DRB1*03:36; DRB1*03:37; DRB1*03:38; DRB1*03:39; DRB1*03:40 and DRB1*03:41. The sequence shown is that of DRB1*03:01 Polymorphism : The following alleles of DRB1-4 are known: DRB1*04:01, DRB1*04:02, DRB1*04:03, DRB1*04:04, DRB1*04:05,DRB1*04:06, DRB1*04:07, DRB1*04:08, DRB1*04:09, DRB1*04:10, DRB1*04:11, DRB1*04:12, DRB1*04:13, DRB1*04:14, DRB1*04:15, DRB1*04:16, DRB1*04:17, DRB1*04:18, DRB1*04:19, DRB1*04:20, DRB1*04:21, DRB1*04:22, DRB1*04:23, DRB1*04:24, DRB1*04:25, DRB1*04:26, DRB1*04:27, DRB1*04:28, DRB1*04:29, DRB1*04:30, DRB1*04:31, DRB1*04:32, DRB1*04:33, DRB1*04:34, DRB1*04:35, DRB1*04:36, DRB1*04:37, DRB1*04:38, DRB1*04:39, DRB1*04:40, DRB1*04:41, DRB1*04:42, DRB1*04:43, DRB1*04:44, DRB1*04:45, DRB1*04:46, DRB1*04:47, DRB1*04:48, DRB1*04:49, DRB1*04:50, DRB1*04:51, DRB1*04:52, DRB1*04:53, DRB1*04:54, DRB1*04:55, DRB1*04:56, DRB1*04:57, DRB1*04:58, DRB1*04:59, DRB1*04:60, DRB1*04:61, DRB1*04:62, DRB1*04:63, DRB1*04:64, DRB1*04:65, DRB1*04:66, DRB1*04:67, DRB1*04:68, DRB1*04:69, DRB1*04:70, DRB1*04:71, DRB1*04:72, DRB1*04:73, DRB1*04:74, DRB1*04:75, DRB1*04:76, DRB1*04:77 and DRB1*04:78. The sequence shown is that of DRB1*04:01 Polymorphism : The following alleles of DRB1-7 are known: DRB1*07:01, DRB1*07:03, DRB1*07:04, DRB1*07:05, DRB1*07:06,DRB1*07:07, DRB1*07:08, DRB1*07:09, DRB1*07:11, DRB1*07:12, DRB1*07:13, DRB1*07:14, DRB1*07:15, DRB1*07:16 and DRB1*07:17. The sequence shown is that of DRB1*07:01 Polymorphism : Allele DRB1*07:01 is associated with persistent hepatitis C virus (HCV) infections [MIM:609532]Polymorphism : The following alleles of DRB1-8 are known: DRB1*08:01 (Dw8.1), DRB1*08:02 (Dw8.2; DRB1L), DRB1*08:03(Dw8.3); DRB1*08:04; DRB1*08:05, DRB1*08:06, DRB1*08:07, DRB1*08:08, DRB1*08:09, DRB1*08:10, DRB1*08:11, DRB1*08:12, DRB1*08:13, DRB1*08:14, DRB1*08:15, DRB1*08:16, DRB1*08:17, DRB1*08:18, DRB1*08:19, DRB1*08:20, DRB1*08:21, DRB1*08:22, DRB1*08:23, DRB1*08:24, DRB1*08:25, DRB1*08:26, DRB1*08:27, DRB1*08:28, DRB1*08:29, DRB1*08:30, DRB1*08:31, DRB1*08:32, DRB1*08:33, DRB1*08:34, DRB1*08:35 and DRB1*08:36. The sequence shown is that of DRB1*08:01 Polymorphism : The following alleles of DRB1-9 are known: DRB1*09:01, DRB1*09:02, DRB1*09:03, DRB1*09:04, DRB1*09:05,DRB1*09:06, DRB1*09:07 and DRB1*09:08. The sequence shown is that of DRB1*09:01 Polymorphism : The following alleles of DRB1-10 are known: DRB1*10:01; DRB1*10:02 and DRB1*10:03. The sequence shown isthat of DRB1*10:01 Polymorphism : The following alleles of DRB1-11 are known: DRB1*11:01, DRB1*11:03, DRB1*11:04, DRB1*11:05, DRB1*11:06,DRB1*11:07, DRB1*11:08, DRB1*11:09, DRB1*11:10, DRB1*11:11, DRB1*11:12, DRB1*11:13, DRB1*11:14, DRB1*11:15, DRB1*11:16, DRB1*11:17, DRB1*11:18, DRB1*11:19, DRB1*11:20, DRB1*11:21, DRB1*11:22, DRB1*11:23, DRB1*11:24, DRB1*11:25, DRB1*11:26, DRB1*11:27, DRB1*11:28, DRB1*11:29, DRB1*11:30, DRB1*11:31, DRB1*11:32, DRB1*11:33, DRB1*11:34, DRB1*11:35, DRB1*11:36, DRB1*11:37, DRB1*11:38, DRB1*11:39, DRB1*11:40, DRB1*11:41, DRB1*11:42, DRB1*11:43, DRB1*11:44, DRB1*11:45, DRB1*11:46, DRB1*11:47, DRB1*11:48, DRB1*11:49, DRB1*11:50, DRB1*11:51, DRB1*11:52, DRB1*11:53, DRB1*11:54, DRB1*11:55, DRB1*11:56, DRB1*11:57, DRB1*11:58, DRB1*11:59, DRB1*11:60, DRB1*11:61, DRB1*11:62, DRB1*11:63, DRB1*11:64, DRB1*11:65, DRB1*11:66, DRB1*11:67, DRB1*11:68, DRB1*11:69, DRB1*11:70 and DRB1*11:72. The sequence shown is that of DRB1*11:01 Polymorphism : Allele DRB1*11:01 is associated with self-limiting hepatitis C virus (HCV) infections [MIM:609532]Polymorphism : The following alleles of DRB1-12 are known: DRB1*12:01, DRB1*12:02, DRB1*12:03, DRB1*12:04, DRB1*12:05,DRB1*12:06, DRB1*12:07, DRB1*12:08, DRB1*12:09, DRB1*12:10, DRB1*12:11, DRB1*12:12, DRB1*12:13, DRB1*12:14, DRB1*12:15, DRB1*12:16, DRB1*12:17, DRB1*12:18 and DRB1*12:19. The sequence shown is that of DRB1*12:01 Polymorphism : The following alleles of DRB1-13 are known: DRB1*13:01, DRB1*13:02, DRB1*13:03, DRB1*13:04, DRB1*13:05,DRB1*13:06, DRB1*13:07, DRB1*13:08, DRB1*13:09, DRB1*13:10, DRB1*13:11, DRB1*13:12, DRB1*13:13, DRB1*13:14, DRB1*13:15, DRB1*13:16, DRB1*13:17, DRB1*13:18, DRB1*13:19, DRB1*13:20, DRB1*13:21, DRB1*13:22, DRB1*13:23, DRB1*13:24, DRB1*13:25, DRB1*13:26, DRB1*13:27, DRB1*13:28, DRB1*13:29, DRB1*13:30, DRB1*13:31, DRB1*13:32, DRB1*13:33, DRB1*13:34, DRB1*13:35, DRB1*13:36, DRB1*13:37, DRB1*13:38, DRB1*13:39, DRB1*13:40, DRB1*13:41, DRB1*13:42, DRB1*13:43, DRB1*13:44, DRB1*13:45, DRB1*13:46, DRB1*13:47, DRB1*13:48, DRB1*13:49, DRB1*13:50, DRB1*13:51, DRB1*13:52, DRB1*13:53, DRB1*13:54, DRB1*13:55, DRB1*13:56, DRB1*13:57, DRB1*13:58, DRB1*13:59, DRB1*13:60, DRB1*13:61, DRB1*13:62, DRB1*13:63, DRB1*13:64, DRB1*13:65, DRB1*13:66, DRB1*13:67, DRB1*13:68, DRB1*13:69, DRB1*13:70, DRB1*13:71, DRB1*13:72, DRB1*13:73, DRB1*13:74, DRB1*13:75, DRB1*13:76, DRB1*13:77, DRB1*13:78, DRB1*13:79, DRB1*13:80, DRB1*13:81, DRB1*13:82, DRB1*13:83, DRB1*13:84, DRB1*13:85, DRB1*13:86, DRB1*13:87 and DRB1*13:88. The sequence shown is that of DRB1*13:01 Polymorphism : The following alleles of DRB1-14 are known: DRB1*14:01, DRB1*14:02, DRB1*14:03, DRB1*14:04, DRB1*14:05,DRB1*14:06, DRB1*14:07, DRB1*14:08, DRB1*14:09, DRB1*14:10, DRB1*14:11, DRB1*14:12, DRB1*14:13, DRB1*14:14, DRB1*14:15, DRB1*14:16, DRB1*14:17, DRB1*14:18, DRB1*14:19, DRB1*14:20, DRB1*14:21, DRB1*14:22, DRB1*14:23, DRB1*14:24, DRB1*14:25, DRB1*14:26, DRB1*14:27, DRB1*14:28, DRB1*14:29, DRB1*14:30, DRB1*14:31, DRB1*14:32, DRB1*14:33, DRB1*14:34, DRB1*14:35, DRB1*14:36, DRB1*14:37, DRB1*14:38, DRB1*14:39, DRB1*14:40, DRB1*14:41, DRB1*14:42, DRB1*14:43, DRB1*14:44, DRB1*14:45, DRB1*14:46, DRB1*14:47, DRB1*14:48, DRB1*14:49, DRB1*14:50, DRB1*14:51, DRB1*14:52, DRB1*14:53, DRB1*14:54, DRB1*14:55, DRB1*14:56, DRB1*14:57, DRB1*14:58, DRB1*14:59, DRB1*14:60, DRB1*14:61, DRB1*14:62, DRB1*14:63, DRB1*14:64, DRB1*14:65, DRB1*14:67, DRB1*14:68, DRB1*14:69, DRB1*14:70, DRB1*14:71, DRB1*14:72, DRB1*14:73, DRB1*14:74, DRB1*14:75, DRB1*14:76, DRB1*14:77, DRB1*14:78, DRB1*14:79, DRB1*14:80, DRB1*14:81, DRB1*14:82, DRB1*14:83, DRB1*14:84 and DRB1*14:85. The sequence shown is that of DRB1*14:01 Polymorphism : The following alleles of DRB1-15 are known: DRB1*15:01, DRB1*15:02, DRB1*15:03, DRB1*15:04, DRB1*15:05,DRB1*15:06, DRB1*15:07, DRB1*15:08, DRB1*15:09, DRB1*15:10, DRB1*15:11, DRB1*15:12, DRB1*15:13, DRB1*15:14, DRB1*15:15, DRB1*15:16, DRB1*15:18, DRB1*15:19, DRB1*15:20, DRB1*15:21, DRB1*15:22, DRB1*15:23, DRB1*15:24, DRB1*15:25, DRB1*15:26, DRB1*15:27, DRB1*15:28, DRB1*15:29, DRB1*15:30, DRB1*15:31 and DRB1*15:32. The sequence shown is that of DRB1*15:01 Polymorphism : The following alleles of DRB1-16 are known: DRB1*16:01; DRB1*16:02; DRB1*16:03; DRB1*16:04; DRB1*16:05;DRB1*16:07; DRB1*16:08; DRB1*16:09; DRB1*16:10; DRB1*16:11 and DRB1*16:12. The sequence shown is that of DRB1*16:02
Genomic Data Transcription Related Data Allele Frequencies SNP ID Valid Chr 6 pos Sequence Recs AA Chg Type More Recs Allele freq Pop Total sample More
About this table HapMap Linkage Disequilibrium images for HLA-DRB1 (up to first 250kb)
Structural Variations (Copy Number Variations, Insertions/Deletions, Inversions) Database of Genomic Variants (DGV): 22 variations for HLA-DRB1 15/20 CNVs (see all 20 ): 7567 69436 37840 69447 69420 4767 4493 64476 3603 69431 69407 69452 81340 69421 93647 2 Indels : 33807 12831
Jump to Section...
Aliases
Databases
Disorders
Domains/Families
Drugs/Compounds
Expression
Function
Genomic Views
Intellectual Property
Medical News
Orthologs
Paralogs
Pathways/Interactions
Products
Proteins
Publications
Search Box
Summaries
Transcripts
Variants
TOP
BOTTOM
Disorders & Mutationsfor HLA-DRB1 gene
(in which this Gene is Involved, According to
OMIM, UniProtKB ,
Novoseek , PharmGKB ,
Genatlas , GeneTests ,
Blood group antigen gene mutations by BGMUT ,
LSDB, HGMD, GAD ,
HuGE Navigator ,
and/or TGDB .)
About This Section
HLA-DRB1 for disorders About GeneDecksing
OMIM: 142857 UniProtKB/Swiss-Prot: 2B1G_HUMAN, Q29974
Genetic variation in HLA-DRB1 is a cause of susceptibility to sarcoidosis type 1 (SS1) [MIM:181000]. Sarcoidosis is an idiopathic, systemic, inflammatory disease characterized by the formation of immune granulomas in involved organs. Granulomas predominantly invade the lungs and the lymphatic system, but also skin, liver, spleen, eyes and other organs may be involved
10/53 Novoseek disease relationships for HLA-DRB1 gene (see all 53 )
Disease
-log (P-Val)
Hits
PubMed IDs for Articles with Shared Sentences (# sentences)
rheumatoid arthritis
66.3
64
1416553 (3), 16277691 (2), 16385499 (2), 10765919 (2) (see all 44 )
genetic susceptibility
65.2
8
17055211 (1), 17047287 (1), 17309132 (1), 18004301 (1) (see all 8 )
polymyalgia rheumatica
58.1
10
10225816 (2), 8147928 (2), 9458210 (2), 15305244 (2) (see all 5 )
diabetes mellitus insulin-dependent
50.2
2
10680451 (1), 7817375 (1)
autoimmune diseases
49.3
5
16362107 (1), 19117368 (1), 16198136 (1), 1617108 (1) (see all 5 )
vogt-koyanagi-harada disease
46.6
2
7906684 (1), 15603876 (1)
autoimmunity
44.1
4
16385499 (1), 17987563 (1), 15120192 (1), 8675578 (1)
hepatitis autoimmune
44
3
1350267 (2), 9672174 (1)
pemphigus foliaceus
36.9
1
9027963 (1)
diabetes autoimmune
35.6
2
10333055 (1), 18279373 (1)
About this table 1 PharmGKB disease relationship for HLA-DRB1 gene About this table Locus Specific Mutation Databases (LSDB): HLA-DRB1 Human Gene Mutation Database (HGMD) : HLA-DRB1 Genetic Association Database (GAD): HLA-DRB1 Human Genome Epidemiology (HuGE) Navigator: HLA-DRB1 (1758 documents) Export disorders and mutations for HLA-DRB1 gene to outside databases
Jump to Section...
Aliases
Databases
Disorders
Domains/Families
Drugs/Compounds
Expression
Function
Genomic Views
Intellectual Property
Medical News
Orthologs
Paralogs
Pathways/Interactions
Products
Proteins
Publications
Search Box
Summaries
Transcripts
Variants
TOP
BOTTOM
Medical Newsfor HLA-DRB1 gene (Possibly Related Articles in
Doctor's Guide )
About This Section
Jump to Section...
Aliases
Databases
Disorders
Domains/Families
Drugs/Compounds
Expression
Function
Genomic Views
Intellectual Property
Medical News
Orthologs
Paralogs
Pathways/Interactions
Products
Proteins
Publications
Search Box
Summaries
Transcripts
Variants
TOP
BOTTOM
Publicationsfor HLA-DRB1 gene (in
PubMed .
Associations of this gene to articles via
1 Entrez Gene ,
2 UniProtKB/Swiss-Prot ,
3 HGNC ,
4 GAD ,
5 PharmGKB ,
6 UniProtKB/TrEMBL , and/or
7 Novoseek )
About This Section 10/2282 PubMed articles for HLA-DRB1 gene, integrated from 7 sources (see all 2282 ): (articles sorted by number of sources associating them with HLA-DRB1) [Determination of HLA-DRB1 gene polymorphism in Luoba ethnic group of Tibet] (PubMed id 15898419) 1 , 4, 7 Kang L.L....Li S.B. (2005) Influence of HLA-DRB1 and TNF microsatellite polymorphisms on the expression of extraarticular manifestations in rheumatoid arthritis patients from northwest Spain. (PubMed id 11791643) 1 , 4, 7 Mattey D.L....Ollier W.E. (2001) [Possible association between HLA-HRB1 and DQB1 genes frequency and susceptibility or resistance to Helicobacter pylori infection in Kunming Yi ethnic group children] (PubMed id 15833172) 1 , 4, 7 Huang Y.K....Zhou L.F. (2005) [Association of HLA-A, B, and DR haplotypes with genotype in Chinese children with systemic lupus erythematosus] (PubMed id 14748996) 1 , 4, 7 Li C.F....Jiang Z.F. (2003) [Polymorphism of length of tetranucleotide repeat from the 5'-side from the myelin basic protein gene in multiple sclerosis in Russians] (PubMed id 14714495) 1 , 4, 7 Andreevskii T.V....Favorova O.O. (2003) HLA-DRB1 and HLA-DQB1 polymorphisms in Pacific Islands populations. (PubMed id 12144623) 1 , 4, 7 Velickovic Z.M....Carter J.M. (2002) Collagenase-1 (MMP-1) and HLA-DRB1 gene polymorphisms in rheumatoid arthritis: a prospective longitudinal study. (PubMed id 11824952) 1 , 4, 7 Constantin A....Cantagrel A. (2002) Association between protein tyrosine phosphatase 22 variant R620W in conjunction with the HLA-DRB1 shared epitope and humoral autoimmunity to an immunodominant epitope of cartilage-specific type II collagen in early rheumatoid arthritis. (PubMed id 16385499) 1 , 4, 7 Burkhardt H....Reis A. (2006) [Polymorphism of HLA-A,-B and DRB1 in Han population of Shanxi province] (PubMed id 16215957) 1 , 4, 7 Lan T....Wang G.Q. (2005) The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis. (PubMed id 16277691) 1 , 4, 7 Turesson C....Matteson E.L. (2005)
Jump to Section...
Aliases
Databases
Disorders
Domains/Families
Drugs/Compounds
Expression
Function
Genomic Views
Intellectual Property
Medical News
Orthologs
Paralogs
Pathways/Interactions
Products
Proteins
Publications
Search Box
Summaries
Transcripts
Variants
TOP
BOTTOM
External Searches for HLA-DRB1 gene
(in PubMed ,
OMIM , and NCBI Bookshelf ) About This Section
Jump to Section...
Aliases
Databases
Disorders
Domains/Families
Drugs/Compounds
Expression
Function
Genomic Views
Intellectual Property
Medical News
Orthologs
Paralogs
Pathways/Interactions
Products
Proteins
Publications
Search Box
Summaries
Transcripts
Variants
TOP
BOTTOM
Genome Databases showing HLA-DRB1 gene
(According to
Entrez Gene ,
HGNC ,
AceView ,
euGenes ,
Ensembl ,
miRBase ,
ECgene ,
Kegg ,
and/or
H-InvDB )
About This Section
Jump to Section...
Aliases
Databases
Disorders
Domains/Families
Drugs/Compounds
Expression
Function
Genomic Views
Intellectual Property
Medical News
Orthologs
Paralogs
Pathways/Interactions
Products
Proteins
Publications
Search Box
Summaries
Transcripts
Variants
TOP
BOTTOM
Other Databases showing HLA-DRB1 gene
(According to HUGE )
About This Section --
Jump to Section...
Aliases
Databases
Disorders
Domains/Families
Drugs/Compounds
Expression
Function
Genomic Views
Intellectual Property
Medical News
Orthologs
Paralogs
Pathways/Interactions
Products
Proteins
Publications
Search Box
Summaries
Transcripts
Variants
TOP
BOTTOM
Specialized Databases showing HLA-DRB1 gene (According to ATLAS , HORDE , IMGT , MTDB, LEIDEN , UniProtKB/Swiss-Prot , and/or UniProtKB/TrEMBL ,Wikipedia and/or GeneReviews via UniProtKB/Swiss-Prot )About This Section
Jump to Section...
Aliases
Databases
Disorders
Domains/Families
Drugs/Compounds
Expression
Function
Genomic Views
Intellectual Property
Medical News
Orthologs
Paralogs
Pathways/Interactions
Products
Proteins
Publications
Search Box
Summaries
Transcripts
Variants
TOP
BOTTOM
About This Section Patent Information for HLA-DRB1 gene: Search GeneIP for patents involving HLA-DRB1 GeneCards and IP: Japan Patent Office Licenses GeneCards European Patent Office Licenses GeneCards Improving the IP Search
Jump to Section...
Aliases
Databases
Disorders
Domains/Families
Drugs/Compounds
Expression
Function
Genomic Views
Intellectual Property
Medical News
Orthologs
Paralogs
Pathways/Interactions
Products
Proteins
Publications
Search Box
Summaries
Transcripts
Variants
TOP
BOTTOM
Productsfor HLA-DRB1 gene (Antibodies, recombinant proteins, and assays by Millipore , Sigma-Aldrich , R&D Systems , Qiagen , GenScript , Cell Signaling Technology , SABiosciences , Novus Biologicals , Epitomics , ProSpec , Uscn , Clones available from Millipore , Sigma-Aldrich , OriGene , GenScript , Sino Biological , PCR Arrays from SABiosciences , Drugs and/or compounds by Sigma-Aldrich , Tocris Bioscience , and/or
Enzo Life Sciences )About This Section
Jump to Section...
Aliases for HLA-DRB1
Databases for HLA-DRB1
Disorders for HLA-DRB1
Domains/Families for HLA-DRB1
Drugs/Compounds for HLA-DRB1
Expression for HLA-DRB1
Function for HLA-DRB1
Genomic Views for HLA-DRB1
Intellectual Property for HLA-DRB1
Medical News for HLA-DRB1
Orthologs for HLA-DRB1
Paralogs for HLA-DRB1
Pathways/Interactions for HLA-DRB1
Products for HLA-DRB1
Proteins for HLA-DRB1
Publications for HLA-DRB1
Search Box for HLA-DRB1
Summaries for HLA-DRB1
Transcripts for HLA-DRB1
Variants for HLA-DRB1
TOP
BOTTOM